Thyrocare Technologies board meeting scheduled for May 07, 2026 to approve audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Board will consider recommending final dividend for financial year 2025-26 during the meeting.
Trading window closed since April 01, 2026 for designated persons and will reopen 48 hours after results declaration.